The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
Howard Markel,
As one who is privileged to edit a journal as distinguished as The Milbank Quarterly, I am keenly aware that the position sits squarely on the shoulder of giants. One of those giants, David Willis—who edited the Quarterly from 1970 to 1990—died this past January. It was in his capacity as editor of what was then titled The Milbank Memorial Fund Quarterly/Health and Society where he shined the brightest. More
Lawrence O. Gostin,
Sandro Galea,
David Mechanic,
John E. McDonough,
David K. Jones,
Joshua M. Sharfstein,
Gail R. Wilensky,
Sara Rosenbaum,
David Rosner,
Featured Article
Huseyin Naci, Olivier J. Wouters, Radhika Gupta, John P.A. Ioannidis,
What is the clinical evidence on therapeutic agents that treat serious conditions and are eligible for Food and Drug Administration accelerated approval? This study is the first to provide a systematic evaluation of the evidence on drugs receiving this type of approval between 2000 and 2013. These drugs often quickly become part of standard treatment, despite shortcomings in their evidence base. More
Sarah E. Gollust, Stacy W. Gray, Deanna Alexis Carere, Barbara A. Koenig, Lisa Soleymani Lehmann, Amy L. McGuire, Richard R. Sharp, Kayte Spector-Bagdady, Na Wang, Robert C. Green, J. Scott Roberts, for the PGEN Study Group,
In mid-April, 23andMe received FDA approval to sell tests for 10 genetic conditions. As the New York Times reported in May, the tests are now creating problems for insurers who have no way of knowing the results. Researchers found that the majority of consumers supported expanded access to genetic testing services and oppose additional regulation, while those who had a negative experience were less supportive of expanded availability without a medical professional. More
Asterie Twizeyemariya, Sophie Guy, Gareth Furber, Leonie Segal,
Context: Mental illness is a high source of disease burden across the globe. Mental illness is now understood as largely developmental, with its… More
Wan Chen Kang Graham, Marcel Bilger,
Context: Financing long-term services and supports (LTSS) for the elderly is a pressing issue in the United States with reforms of long-term care… More
Powel Kazanjian,
Context: Throughout its course, there has been talk of ending the AIDS epidemic. Initially aspirational in nature, this discourse has now taken the… More
Previous issue
March 2017
Next issue
September 2017
